Sonoma Pharmaceuticals, Inc. — Director's Dealing 2012

Jan 13, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oculus Innovative Sciences, Inc. (OCLS)
CIK: 0001367083
Period of Report: 2012-01-12

Reporting Person: French Gregory M (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-01-12	Stock Option (Right to Buy)	$1.09	A	40000	Acquired	2022-01-12	Common Stock (40000)	Direct

Footnotes

F1: The option shall vest 1/36th per month over a three year vesting schedule from date of grant.

F2: The option was issued as compensation for services provided to the Company.